Literature DB >> 20473362

Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Brendan M Weiss1, W Michael Kuehl.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) affects at least 3% of the population above the age of 50 and is the precursor to multiple myeloma (MM), an incurable malignancy of plasma cells. Recent advances in MGUS include: an improved understanding of the pathogenesis of MGUS and its progression to MM, involving molecular events intrinsic to the malignant plasma cell as well as the microenvironment; novel techniques to assess risk for progression to MM using serum-free light-chain analysis and immunophenotyping; and a renewed interest in chemoprevention of MM. In the future, continued improvement in our understanding of MGUS will lead to the development of better biomarkers for prognosis and therapies for chemoprevention of MM.

Entities:  

Keywords:  MGUS; monoclonal gammopathy of undetermined significance; multiple myeloma; pathogenesis

Mesh:

Substances:

Year:  2010        PMID: 20473362      PMCID: PMC2869099          DOI: 10.1586/ehm.10.13

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  71 in total

1.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 2.  Pathogenesis and progression of monoclonal gammopathy of undetermined significance.

Authors:  J Bladé; L Rosiñol; M T Cibeira; C F de Larrea
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

3.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.

Authors:  Thomas Rasmussen; Michael Kuehl; Marianne Lodahl; Hans E Johnsen; Inger Marie S Dahl
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

4.  Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Manfred Ahlgrimm; Natalie Fadle; Evi Regitz; Claudia Pfoehler; Niels Murawski; Michael Pfreundschuh
Journal:  Lancet Oncol       Date:  2009-09-18       Impact factor: 41.316

5.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

6.  Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

7.  Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies.

Authors:  R Bataille; D Chappard; M F Basle
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

Review 8.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

9.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  4 in total

1.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

2.  MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

Authors:  Jihane Khalife; Jayeeta Ghose; Marianna Martella; Domenico Viola; Alberto Rocci; Estelle Troadec; Cesar Terrazas; Abhay R Satoskar; Emine Gulsen Gunes; Ada Dona; James F Sanchez; P Leif Bergsagel; Marta Chesi; Alex Pozhitkov; Steven Rosen; Guido Marcucci; Jonathan J Keats; Craig C Hofmeister; Amrita Krishnan; Enrico Caserta; Flavia Pichiorri
Journal:  JCI Insight       Date:  2019-11-01

Review 3.  Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma.

Authors:  Barbara Castella; Assunta Melaccio; Myriam Foglietta; Chiara Riganti; Massimo Massaia
Journal:  Front Oncol       Date:  2018-11-06       Impact factor: 6.244

4.  Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report.

Authors:  Hilal Hafian; Hubert Schvartz; Martine Patey; Anne Quinquenel
Journal:  BMC Oral Health       Date:  2021-11-23       Impact factor: 2.757

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.